ClinicalTrials.gg
RecruitingNCT06235385EACVI-MMVDUpdated Jun 3, 2024

European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study

An observational study in Heart Valve Diseases, Multiple Valve Disease, Unspecified and Aortic Valve Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.

Planned enrollment
5th of 17
1,500 · median 800
Started
2024
with 5 others
Observational
17 of 48
10 open now
Primary completion
2024-08
later than 3 of 21 live
Registered
42nd of 48
by date
Lead sponsor
2 of 48
Assistance Publique - Hôpitaux de Paris

Among the 48 studies in Heart Valve Diseases with a site in France, this one is the 5th largest by planned enrollment of the 17 observational ones that give a count, is one of 6 that started in 2024, is one of 17 observational ones, reaches primary completion later than 3 of the 21 other live ones, and was the 42nd registered.

Heart Valve Diseases

556 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Valve Diseases with a site in France, or all of them as a file.
02

Study summary

This study aims to investigate the prevalence and characteristics of multiple and mixed valvular heart disease (MMVD), which includes combinations of stenotic or regurgitant lesions on cardiac valves. The research will be conducted as a multicenter observational study, involving several centers worldwide, and will have a one-year follow-up period (with a possible extension to 5 years). The primary aim is to determine the proportion of MMVD among patients evaluated for valvular heart disease. Secondary aims include the evaluation of the epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline, management strategies, and their impact on prognosis. The study will also evaluate clinical outcomes such as mortality, hospitalization for heart failure, and changes in echocardiographic parameters. This research aims to provide valuable insights into the diagnosis, management, and prognosis of MMVD, addressing an important knowledge gap in this area.

Read the detailed description

Multiple and mixed valvular heart disease (MMVD), ie, the combination of stenotic or regurgitant lesions occurring on ≥2 cardiac valves (multiple valvular heart disease (VHD)) or the combination of stenotic and regurgitant lesions on the same valve (mixed VHD), are frequent in clinical routine. Nevertheless, their clinical, biological, cardiovascular imaging, and management is not well established.

This study will assess the proportion of MMVD including each combination of multiple and mixed VHD in a multicentre registry of all consecutive patients assessed on a cardiovascular imaging department for VHD. Furthermore, as secondary aims, baseline characteristics, decision-making and therapeutic strategy at baseline and their impact in terms of prognostic.

This is a prospective multicentre observational study involving 174 centres worldwide (35 countries) conducted as a cohort study with a 1-year follow-up (with possible extension to 5 years). Consecutive patients with a diagnosis of MMVD by echocardiography who meet the inclusion criteria will be included during the 6 months period of recruitment. In the context of a "real-life" cohort, baseline evaluation will be left to the discretion of the attending physician (and could encompass clinical evaluations, biomarkers, electrocardiograms, transthoracic and transoesophageal echocardiography, stress echocardiography, cardiac catheterization, invasive angiography, cardiac CT, and Cardiac MRI). Final diagnosis of the physician will be given, and physician will manage the patient in accordance with international guidelines (transcatheter valve intervention, surgery or no intervention). One year follow-up will be performed during a patient visit or by contact with the treating physician or the patient: vital status, hospitalizations for cardiac reasons (including heart failure), history of stroke and the performance of a new valvular intervention.

The primary endpoint will be the proportion of MMVD among all patients admitted for VHD evaluation in the imaging department. Secondary endpoints encompass; (i) epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline. (ii) proportion of MMVD treated by surgery, percutaneous or medical as well as the detail for management and how complication are managed (iii) prognostic evaluation at one year of follow-up in terms of clinical composite outcome (cardiovascular mortality, hospitalization for heart failure, myocardial infarction, pulmonary embolism and stroke), all-cause mortality, hospitalisation for heart failure, and change in echocardiographic parameters.

This is the first prospective multicentre study assessing the proportion of MMVD and their characteristics in term of diagnosis, management, and prognostic.

03

Conditions studied

  • Heart Valve Diseases
  • Multiple Valve Disease, Unspecified
  • Aortic Valve Disease
  • Aortic Valve Stenosis
  • Aortic Valve Insufficiency
  • Mitral Valve Disease
  • Mitral Valve Stenosis
  • Mitral Valve Insufficiency and Aortic Valve Insufficiency
  • Mitral Valve Insufficiency
  • Aortic Valve Stenosis With Insufficiency
  • Mitral Valve Disease Mixed
  • Tricuspid Valve Insufficiency
  • Tricuspid Valve Disease
  • Tricuspid Stenosis

Keywords

  • Multiple Valvular Heart Disease
  • Mixed Valvular Heart Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients referred to a Cardiovascular imaging Department with a diagnosis of at least one at least moderate VHD, and who meet the criteria for MMVD defined by multiple and/or mixed disease, will be included in the study.

Eligibility criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Patient referred to the cardiovascular imaging department.
  3. Diagnosis of MMVD confirmed by transthoracic echocardiography, defined as:

    1. Multiple VHD: at least 2 moderates to severe VHD involving ≥ 2 different valves, using the current ESC guidelines.

      and/or

    2. Mixed VHD: at least moderate stenosis and at least moderate regurgitation of a single valve, using the current ESC guidelines.
  4. Patient not refusing to have their data involved in the protocol after information.

Exclusion Criteria (patients fulfilling any of the following criteria are not eligible for inclusion in this study):

  1. History of prior valve surgery or percutaneous valve intervention (concerning a valve other than those involved in the definition of MMVD).
  2. Acute infective endocarditis at the time of evaluation for inclusion (confirmed according to modified Duke criteria) or history of endocarditis ≤ 6 months.
  3. Complex congenital heart diseases.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Interventions

  • OtherIntervention not provided

    This study is purely observational

06

What researchers measure

Primary outcomes

  1. Proportion of multiple and mixed valvular disease (MMVD)

    Number of consecutive patients diagnosed with multiple and mixed valvular disease divided by the total number of consecutive patients assessed for valvular heart disease on a cardiovascular imaging department

    Time frame: Baseline

Secondary outcomes

  1. Major Adverse Cardiovascular Event (MACE)

    Clinical composite outcome defined as: cardiovascular mortality, hospitalization for heart failure (HF), myocardial infarction, pulmonary embolism and stroke.

    Time frame: Up to 5 years

  2. All-cause mortality

    The adjudication of all-cause death was performed using the follow-up performed in clinical routine

    Time frame: Up to 5 years

  3. Cardiovascular mortality

    The adjudication of cardiovascular mortality was performed using the follow-up performed in clinical routine

    Time frame: Up to 5 years

  4. Hospitalization for heart failure

    Hospitalization for heart failure according to the European Society of Cardiology (ESC) guidelines

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data cannot be shared for ethical/privacy reasons. The data cannot be shared publicly for the privacy of individuals that participated in the study and also because of regulatory constraints in the field of clinical research in France, it is unfortunately not possible to make the entire database available to all as an open source.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Aug 2024, 5 months after the start.

Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 5 months is below that.

Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Jan 31, 2024
StartActual
Feb 7, 2024
Primary completionEst.
Aug 1, 2024
CompletionEst.
Aug 1, 2029
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06235385
Collaborators
European Association of Cardiovascular Imaging
Responsible party
Sponsor
First posted
Jan 31, 2024
Start date
Feb 7, 2024
Primary completion
Aug 1, 2024 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Jun 3, 2024

Study contacts

Théo PEZEL, MD PhD
Contact
theo.pezel@aphp.fr
668722489 ext. +33
Alexandre UNGER, MD
Contact
alexandre.unger@ulb.be
478487691 ext. +32

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion